Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy

By sjmartinez • June 3, 2024

Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun;14(6):1079-1087. doi: 10.1002/alr.23312. Epub 2023 Dec 25. PMID: 38145393.

Tags: chronic rhinosinusitis, cystic fibrosis, highly effective modulator therapy, olfaction, olfactory disorders, olfactory dysfunction, olfactory test, patient‐reported outcome measure, Publications, Pulmonary, Critical Care & Sleep Medicine, Quality of Life

Related Posts

Moderators of the Effects of Telehealth Mindfulness-based Interventions for Chronic Pain: A Secondary Responder Analysis of the LAMP Randomized Controlled Trial

Calvert CM, Hagel Campbell EM, Cross LJS, Bangerter A, Bronfort G, Evans R, Meis LA, Haley A, Leininger B, Matthias M, Polusny M, Allen K,[...]

Leveraging scholarship to lead

Moriates C. Leveraging scholarship to lead. J Hosp Med. 2026 Sep 9. doi: 10.1002/jhm.70478. Epub ahead of print. PMID: 42717657.

Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension

Alotaibi M, Tang A, Sun N, Gurholt I, Yuguchi E, Roberts K, Preston I, Warburton R, Yuan JX, Kim NH, Chan SY, Jain M, Cheng[...]